HIPODERM

High Potency Dermatologicals

Coordinatore	WATERFORD INSTITUTE OF TECHNOLOGY    more  Organization address address: CORK ROAD city: WATERFORD postcode: - contact info Titolo: Dr. Nome: Peter Cognome: Mcloughlin Email: send email Telefono: +353 51 302029 Fax: +353 51 302679
Nazionalità Coordinatore	Ireland [IE]
Totale costo	838˙363 €
EC contributo	838˙363 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2009-IAPP
Funding Scheme	MC-IAPP
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-03-01   -   2015-02-28

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	WATERFORD INSTITUTE OF TECHNOLOGY  Organization address address: CORK ROAD city: WATERFORD postcode: - contact info Titolo: Dr. Nome: Peter Cognome: Mcloughlin Email: send email Telefono: +353 51 302029 Fax: +353 51 302679	IE (WATERFORD)	coordinator	231˙819.00
2	An-eX Analytical Services Ltd.  Organization address address: Ty Atebion Ffordd Yr Hen Gae Bocam Park 2 city: Bridgend postcode: CF35 5LJ contact info Titolo: Dr. Nome: Keith Cognome: Brain Email: send email Telefono: +44 2920 361234	UK (Bridgend)	participant	211˙852.00
3	EIRGEN PHARMA LIMITED  Organization address address: Old Kilmeaden Road UNIT 64-65 city: WATERFORD contact info Titolo: Mr. Nome: Tom Cognome: Brennan Email: send email Telefono: +353 51 591 944 Fax: +353 51 591 945	IE (WATERFORD)	participant	199˙993.00
4	CARDIFF UNIVERSITY  Organization address address: Newport Road 30-36 city: CARDIFF postcode: CF24 ODE contact info Titolo: Ms. Nome: Eevi Cognome: Laukkanen Email: send email Telefono: +44 29 20870114 Fax: +44 29 20874149	UK (CARDIFF)	participant	194˙699.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The HIPODERM application seeks support under the Marie Curie Industry-Academia Partnerships and Pathways scheme to facilitate the growth of a dynamic research team for 'the development of novel dermal-translocation, high-potency drug delivery systems'. Our aim is to develop a core scientific platform from which novel non-invasive drug delivery systems can be developed and clinically assessed. At the core of this project lies the hypothesis that microneedle assisted topical drug delivery has failed to fulfil expectations because researchers have routinely over estimated the scale of permeation enhancement possible using passive microneedle treatment and also, in general, have targeted unsuitable therapeutic molecules. This project aims to address both of these issues by developing new formulation and fabrication approaches. Combining physical disruption of the stratum corneum barrier with microneedle arrays and a number of active permeation enhancement techniques (such as iontophoresis and phonophoresis) will produce a range of novel hybrid permeation enhancement systems (HPES). The project will focus on high potency therapeutics possessing low therapeutic concentrations that make only realistic demands on delivery systems. Such high potency materials are of increasing importance in therapeutics but are inherently difficult to work with because of the health and safety implications of their high activity. The project pools the expertise of a number of international partners with particular expertise in specific aspects of the approach.

Three clinically interesting target areas have been identified for evaluation: 1. Locally delivered chemotherapeutic agents for the treatment of cancers of the skin and underlying tissues 2. Enhanced localised delivery of potent photosensitisers for photodynamic therapy (PDT) 3. Local and systemic delivery of therapeutic peptides'